The effect of alcuronium dichloride (0.3 mg/kg) was studied in seven normal children (Group A), nine with acyanotic congenital heart disease (Group B) and eight with cyanotic disease (Group C). The onset of action was recorded using an integrated electromyograph and blood samples taken for later estimation of plasma concentrations of the drug.
There is a strong clinical impression that children with cyanotic congenital heart disease are resistant to the nondepolarising muscle relaxants, although this appears to be mentioned in only one standard textbook of paediatric anaesthesia. I However, Maunuksela and Gattiker 2 found no difference in the speed of onset of neuromuscular blockade after pancuronium 0.1 mg/kg in children with cyanotic and acyanotic disease. It was decided to investigate further this apparent conflict between clinical impression and published data.
PATIENTS AND METHODS
Hospital Ethics Committee approval was obtained for the study. There were three groups of patients. Group A consisted of seven children with no cardiac or other disease known to affect neuromuscular function and who were having elective urological or peripheral surgery. Group B contained nine children with acyanotic heart disease and Group C was made up of eight with cyanotic heart conditions. The children in these latter groups were undergoing elective cardiopulmonary bypass procedures, All the patients were aged between one and ten years and weighed more than 10 kg. Their preoperative haematocrits were noted. The children were premedicated with either papaveretum (0.3-0.4 mg/kg) and hyoscine (6-8 /Lg/kg), or pethidine (1-1.5 mg/kg) and atropine (12-18 /Lg/kg), given intramuscularly one hour before the induction of anaesthesia.
In each child, stimulating electrodes were placed over the posterior tibial nerve at the ankle and recording electrodes over the ball of the foot, to measure the integrated electromyograph (lEMG). To allow stabilisation of the electrodes, they were positioned at least ten minutes before the anaesthetic was started. Measurements were made using the Monash IEMG machine described by Lam et al. J Ulnar nerve stimulation with recording from adductor pollicis brevis was not used, because the electrodes would have interfered with the placement of intravenous and arterial cannulae in the forearm vessels.
Anaesthesia was commenced with thiopentone, additional opioid, nitrous oxide and oxygen. A baseline response to single supramaximal stimuli repeated at ten-second intervals was established. Alcuronium dichloride (0.3 mg/kg), approximately the ED95 for children of this age, 4 then was injected into a running intravenous infusion. The IEMG response to continued 0.1 Hz stimuli was recorded every thirty seconds for ten minutes. Heparinised blood samples were taken from a separate cannula in another limb at two, five and ten minutes after the alcuronium was given. These were refrigerated and the plasma separated for later assay of alcuronium concentrations by reversed phase liquid chromatography, using a method modified from that described by de Bros et al. 5 The results obtained for onset times, maximum paralysis and alcuronium concentrations were analysed by one-way analysis of variance (ANOVA). When differences were noted, the means were compared by the Newman-Keuls test and P<0.05 was considered significant. The relationship between the onset times and haematocrit were assessed by linear regression analysis.
RESULTS
Patient details are shown in Table 1 . As expected from clinical experience, the cyanotic patients had a significantly higher haematocrit than the other two groups.
The time course of the onset of neuromuscular blockade is shown in Figure 1 , which demonstrates that the onset of action appears to be delayed in the cyanosed children, although the degree of paralysis eventually approaches that of the others.
The times taken to reach 75f1!o and 95f1!o depression of twitch height (T75 and T95, respectively) are shown in Table 2 . One patient in Group C failed to reach 75f1!o paralysis within the ten-minute observation period, so that both mean times for those reaching this degree of relaxation and an extrapolated figure, based on rate of onset during the observation period, are presented. There was no difference in T75 between Groups A and B, but both were significantly shorter (P < 0.05) than for either the actual or calculated time for Group C. Six out of seven Group A patients and seven out of nine in Group Breached 95f1!o paralysis, in 3.1(1.4) and An alternative presentation of the onset data, comparing the paralysis and alcuronium concentrations at specific times after administration, is shown in Table  3 . Five minutes after injection of alcuronium, the children in Groups A and B demonstrated significantly greater relaxation than those in Group C. However, there was no difference at ten minutes. Alcuronium concentrations in each of the groups were also similar at five and ten minutes respectively, although at ten minutes they were somewhat lower. This would be expected because of continuing distribution and elimination of the drug.
The maximum degree of relaxation reached, the time after injection at which this occurred and the corresponding plasma alcuronium concentration are shown in Table 4 . Again, there was no difference between the groups in these measurements, despite trends similar to those demonstrated in Table 3 , suggesting that the cyanosed patients were exhibiting a lesser sensitivity to an increased concentration of the drug. 
DISCUSSION
These results confirm our clinical impression that the onset of alcuronium blockade is delayed in children with cyanotic congenital heart disease. As mentioned earlier, the wide inter-individual variaton within each group and especially in Group C, prevented this delay reaching statistical significance, except during the early phases of onset. In fact, considerable individual variation in the dose required and time of onset was also observed by Maunuksela and Gattiker 2 in their study of the use of pancuronium in children with congenital heart disease. This prevented their making any comparison between the effects of different cardiac anomalies on these parameters.
Pharmacodynamic or pharmacokinetic factors, or a combination of both, could explain the delay in onset which we have noted in cyanosed children. The first of these alternatives is supported by the trends which suggest that our cyanosed patients required a higher plasma concentration of alcuronium to reach a similar degree of neuromuscular blockade than did other children, even though these measurements were made at a later time, due to the slower onset of maximum paralysis. This may represent a pharmacodynamic change, that is a decreased sensitivity to alcuronium, amongst these patients.
In a study of fentanyl administration in children with cyanotic heart disease, Koren and his colleagues 6 noted that plasma concentrations of the drug were two to three times higher than in adults given comparable doses. They suggested that reduced cardiac output and decreased tissue perfusion, with a delayed equilibration between plasma and tissues, were the likely causes of these higher concentrations. While we have not demonstrated a statistically significant difference in plasma concentrations of alcuronium in our patient groups, there is a trend for our cyanosed patients to have higher values. If this represents delayed distribution because of decreased tissue blood flow, then, as has been pointed out by Holley 7 and by Stanski and Sheiner, R there will be an artefactual shift to the right in the doseresonse curve, mimicking a pharmacodynamic change. The finding that the early, but not the later, stages of blockade were significantly delayed in our cyanosed patients gives greater support to the hypothesis that kinetic factors may be more important than pharmacodynamic changes in explaining our findings.
We have demonstrated a weak but significant relationship between the early phase of onset of neuromuscular blockade and preoperative haematocrit. The weakness of the relationship suggests only that a high haematocrit is a predictor of slow onset of action, but is merely one of several factors influencing this rate. One might have expected this finding, surmising that those with the highest haematocrits would have more severe cardiac disease and that rheological factors would delay distribution. Plasma concentrations of alcuronium should not be affected by variations in haematocrit, as the drug, being a quaternary compound, would not be expected to enter red cells readily.
In summary, we have demonstrated that children with cyanotic congenital heart disease often have a delayed response to a1curonium. It seems likely that this delay is due to slower distribution, or altered redistribution, of the drug to the receptor site, although an alteration in sensitivity to alcuronium cannot be ruled out. It seems likely that this finding would be repeated with other nondepolarising muscle relaxants. The practical consequence of this is to suggest that, if onset of nondepolarising blockade within a reasonable time period is required, a larger than normal dose of the drug should be given in children with cyanotic congenital heart disease. However, if a larger than normal dose is given, then adverse cardiovascular effects may become more prominent. Consequently, agents with minimal side-effects should be chosen.
